- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05645224
VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures
August 25, 2026 updated by: Henry Xiang, Nationwide Children's Hospital
Pilot Feasibility Clinical Trial of Virtual Reality for Pain Management During Repeated Pediatric Laser Procedures
This study will assess the feasibility and efficacy of our Virtual Reality Pain Alleviation Therapy (VR-PAT) for pain management during pediatric and young adult outpatient laser procedures and evaluate the impact of VR use on reducing anxiety in patients undergoing dermatologic laser procedures.
The investigators hypothesize that patients using VR-PAT will report less pain and anxiety during the laser procedure than patients who do not play the game.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
In this three-group crossover randomized clinical trial, patients will be randomly assigned to either the VR-PAT intervention group, control group (same VR google without game), or standard of care at the first laser procedure and will then cross-over to the alternative group for the second laser procedure.
Survey questions to assess pain and anxiety and control for confounding factors will be asked before and after each procedure.
VR versus Control and VR versus Standard of Care will be compared.
Study Type
Interventional
Enrollment (Estimated)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 25 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- dermatology patients (5+ years) who are undergoing first laser procedure at the Nationwide Children's Outpatient Laser
- have a legal guardian present for patients less than 18 years old for the procedure (for informed consent)
- can communicate orally
Exclusion Criteria:
- any wounds that may interfere with study procedures
- usage of a diode laser (VR safety has not been established yet)
- vision, hearing, or cognitive/motor impairments preventing valid administration of study measures
- history of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras
- minors in foster care
- unable to communicate in English
- pregnant women
- prisoners
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VR-PAT
Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game.
|
Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
|
|
No Intervention: Control
Participant wears the Pico Neo 3 Pro Eye headset to protect eyes, but it is not turned on.
|
|
|
No Intervention: Standard of Care
This will be a standard of care group that will match the current clinic practices.
Subjects will wear the standard protective eyewear and offered current distraction options.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in procedural pain
Time Frame: Assessed immediately following each laser procedure
|
0-10 Numerical Rating Scale (NRS) (self-reported and caregiver-reported (if <18 years)), 0(min)-10(max), with higher score indicating worse pain.
Asked for worst pain, average pain, and time spent thinking about pain.
|
Assessed immediately following each laser procedure
|
|
Change in procedural anxiety
Time Frame: Assessed at 3 time points (prior to entering procedure room, prior to the procedure, and immediately following the procedure) for each laser procedure
|
Modified Yale Preoperative Anxiety Scale (mYPAS) (observed by researcher), 23.33(min)-100(max), with higher scores denoting higher levels of anxiety.
|
Assessed at 3 time points (prior to entering procedure room, prior to the procedure, and immediately following the procedure) for each laser procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported VR experience
Time Frame: Immediately following laser procedure in VR-PAT group
|
0-10 Numerical Rating Scale (NRS) (self-reported - VR-PAT arm only), 0(min)-10(max), with higher score meaning better outcome.
Asked for degree of realism, pleasure, and satisfaction with VR.
|
Immediately following laser procedure in VR-PAT group
|
|
Nurse-reported utility
Time Frame: Immediately following laser procedure in VR-PAT group
|
Binary (Yes/No) questions of whether the nurse found VR-PAT to be helpful and easy to use during the procedure.
|
Immediately following laser procedure in VR-PAT group
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Henry Xiang, MD, MPH, PhD, MBA, Nationwide Children's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2023
Primary Completion (Actual)
November 14, 2025
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
November 30, 2022
First Submitted That Met QC Criteria
December 8, 2022
First Posted (Actual)
December 9, 2022
Study Record Updates
Last Update Posted (Actual)
August 27, 2026
Last Update Submitted That Met QC Criteria
August 25, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002880
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.